Press Releases from DelveInsight (528 total)
Spinal Implants Market Size Report 2032: Market Porter's Five Forces Analysis, M …
DelveInsight's Spinal Implants Market Insights Report 2032 provides the current and forecast market analysis, individual leading Spinal Implants Companies market shares, challenges, Spinal Implants Market…
Genome Editing Market Size Report 2032: Market Porter's Five Forces Analysis, Ma …
DelveInsight's Genome Editing Market Insights Report 2032 provides the current and forecast market analysis, individual leading Genome Editing Companies market shares, challenges, Genome Editing Market…
Retinopathy of Prematurity Therapeutics Market: Early-Stage Pipeline and FDA Des …
The Retinopathy of Prematurity treatment market is expected to witness significant growth in the coming years, primarily driven by advancements in diagnostic technologies and the…
Chronic Kidney Disease Market Evolution: Novel Drugs, AI Integration, and Combin …
The chronic kidney disease (CKD) treatment market is witnessing robust expansion across the 7MM. This upward trajectory is primarily fueled by increasing disease prevalence, growing…
Spinal Muscular Atrophy Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Key Spinal Muscular Atrophy Companies in the market include - Biogen, Novartis, Genentech, F. Hoffmann-La Roche, Scholar Rock, Biohaven, Bristol-Myers Squibb, NMD Pharma, and…
Alzheimer's Disease Market to Evolve Rapidly Over the Next Decade by 2034, Delve …
The Key Alzheimer's Disease Companies in the market include - BioVie, AB Science, Cassava Sciences, Eli Lilly, TauRx Therapeutics, Novo Nordisk, KeifeRx, AriBio, Cerecin, Alzheon,…
Hunter Syndrome Pipeline Outlook Report 2025: Advancing Therapies, Drug Innovati …
DelveInsight's, "Hunter Syndrome Pipeline Insight 2025" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hunter Syndrome pipeline landscape. It covers the…
Anemia Market Growth Fueled by FDA Approvals, Improved Screening, and Expanding …
The anemia market is projected to experience significant growth across the seven major markets (7MM). This growth is driven by several factors, including increased disease…
wsdfghj
asdfgh
asdfg
asdfg…
PH-ILD Market Size in the 7MM was ~USD 3 Billion in 2024 and is projected to inc …
DelveInsight's "Pulmonary Hypertension associated with Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of PH-ILD, historical and…
Sensorineural Hearing Loss Clinical Trials Analysis 2025: Emerging Regenerative …
DelveInsight's "Sensorineural Hearing Loss Clinical Trials Analysis, 2025" describes a rapidly evolving pipeline targeting both restoration of inner-ear structures and symptomatic improvement. Ongoing programs span…
Cell and Gene Therapy in Parkinson's Disease Clinical Trials Analysis 2025: Dise …
DelveInsight's "Cell and Gene Therapy in Parkinson's Disease - Clinical Trials Analysis, 2025" highlights a diversified development landscape pursuing symptomatic relief and disease modification. Programs…
Staphylococcal Infections Clinical Trials Analysis 2025: New Antibacterials, Ant …
DelveInsight's "Staphylococcal Infections Clinical Trials Analysis, 2025" outlines a focused effort to tackle antibiotic resistance and severe invasive disease. Active programs include novel small-molecule antibacterials…
Cough in Idiopathic Pulmonary Fibrosis Clinical Trials Analysis, 2025: Targeted …
DelveInsight's "Cough in Idiopathic Pulmonary Fibrosis Clinical Trials Analysis, 2025" captures an expanding set of symptomatic and mechanism-based approaches to address an under-treated, QoL-limiting symptom.…
Myotonic Dystrophy Clinical Trials Analysis 2025: RNA-Targeting Oligonucleotides …
DelveInsight's "Myotonic Dystrophy - Clinical Trials Analysis, 2025" highlights a concentrated effort on molecularly targeted approaches that address the underlying toxic RNA mechanisms alongside symptomatic…
Lung Adenocarcinoma Clinical Trials Analysis 2025: Targeted Therapies, Immunothe …
DelveInsight's "Lung Adenocarcinoma - Clinical Trials Analysis, 2025" describes a dynamic and fast-moving development landscape focusing on two complementary goals: (1) inhibit tumor growth and…
Neurofibromatosis Type 1 Clinical Trials Analysis 2025: Targeted RAS-Pathway and …
The Neurofibromatosis Type 1 (NF1) clinical trial landscape in 2025 focuses on two main goals: controlling plexiform and cutaneous neurofibromas and preventing malignant peripheral nerve…
Neisseria Meningitidis Meningitis Clinical Trials Analysis 2025: Multivalent Vac …
DelveInsight's "Neisseria Meningitidis Meningitis - Clinical Trials Analysis, 2025" outlines a rapidly evolving landscape aimed at two primary goals: (1) provide broad serogroup coverage through…
Essential Tremor Clinical Trials Analysis 2025: Novel Pharmacologics, Neuromodul …
DelveInsight's "Essential Tremor - Clinical Trials Analysis, 2025" highlights a dynamic development landscape focused on two complementary goals: (1) reduce tremor severity and improve motor…
Liver Fibrosis Clinical Trials Analysis 2025: Antifibrotic Agents, Gene Modulato …
DelveInsight's "Liver Fibrosis - Clinical Trials Analysis, 2025" outlines a rapidly evolving development landscape with two main objectives: (1) halt or reverse hepatic fibrosis progression,…
Cataract Clinical Trials Analysis 2025: Topical Small Molecules, Regenerative Th …
DelveInsight's "Cataract - Clinical Trials Analysis, 2025" highlights a shifting development landscape aiming to complement or reduce reliance on surgery through pharmacologic, regenerative, and device-based…
Diabetic Gastroparesis Clinical Trials Analysis 2025: Prokinetic Agents, Ghrelin …
DelveInsight's "Diabetic Gastroparesis - Clinical Trials Analysis, 2025" outlines a dynamic research landscape addressing the chronic, debilitating delays in gastric emptying associated with diabetes.
Current trials…
Ataxia Clinical Trials Analysis 2025: Gene Therapies, Ion Channel Modulators, an …
DelveInsight's "Ataxia - Clinical Trials Analysis, 2025" highlights a rapidly evolving pipeline targeting the genetic and neurodegenerative roots of ataxia.
Ongoing phase II-III studies explore gene…
Bacteremia Clinical Trials Analysis 2025: Novel Antibiotics, Monoclonal Antibodi …
DelveInsight's "Bacteremia - Clinical Trials Analysis, 2025" highlights an active development landscape aimed at rapidly eliminating bloodstream infections and preventing progression to sepsis.
Ongoing trials evaluate…
Biliary Tumor Clinical Trials Analysis 2025: Targeted Therapies, Immuno-Oncology …
DelveInsight's "Biliary Tumors - Clinical Trials Analysis, 2025" highlights a rapidly evolving development landscape focused on both intrahepatic and extrahepatic cholangiocarcinomas.
Current trials evaluate FGFR and…
Lewy Body Disease Clinical Trials Analysis 2025: α-synuclein Immunotherapies, N …
DelveInsight's "Lewy Body Disease - Clinical Trials Analysis, 2025" highlights a rapidly evolving trial landscape targeting the underlying biology and complex symptomatology of dementia with…
Chronic Pulmonary Infections Clinical Trials Analysis 2025: Inhaled Antimicrobia …
DelveInsight's "Chronic Pulmonary Infections - Clinical Trials Analysis, 2025" outlines an active and heterogeneous development landscape addressing long-standing airway infections (non-CF bronchiectasis, chronic Pseudomonas infection,…
Chronic Pulmonary Infections Clinical Trials Analysis 2025: Inhaled Antimicrobia …
DelveInsight's "Chronic Pulmonary Infections - Clinical Trials Analysis, 2025" outlines an active and heterogeneous development landscape addressing long-standing airway infections (non-CF bronchiectasis, chronic Pseudomonas infection,…
ATTR Amyloidosis Clinical Trials Analysis 2025: RNA-silencing, TTR Stabilizers, …
DelveInsight's "ATTR Amyloidosis - Clinical Trials Analysis, 2025" describes a crowded, fast-moving development landscape focused on two complementary goals: (1) suppress hepatic TTR production or…
Alcohol Use Disorder Clinical Trials Analysis 2025: Psychedelic-Assisted Therapy …
DelveInsight's "Alcohol Use Disorder - Clinical Trials Analysis, 2025" describes a broad, rapidly evolving trial landscape that pairs novel pharmacology with behavioral interventions to reduce…
Heart Failure Clinical Trials Analysis 2025: SGLT2 Inhibitors, Novel Inotropes, …
DelveInsight's "Heart Failure - Clinical Trials Analysis, 2025" outlines a dynamic development landscape targeting the multifactorial pathophysiology of heart failure (HF), including myocardial dysfunction, fluid…
Bipolar Disorder Clinical Trials Analysis 2025 Novel Mechanisms and Digital Ther …
DelveInsight's "Bipolar Disorder - Clinical Trials Analysis, 2025" reviews a dynamic pipeline aiming to address the unmet needs of patients struggling with recurring episodes of…
Celiac Disease Clinical Trials Analysis 2025 Novel Immunotherapies and Gut-Targe …
DelveInsight's "Celiac Disease - Clinical Trials Analysis, 2025" highlights a rapidly progressing pipeline addressing the limitations of the gluten-free diet, the only current standard of…
Coronary Artery Disease Clinical Trials Analysis 2025: Novel Antithrombotics, Re …
DelveInsight's "Coronary Artery Disease (CAD) - Clinical Trials Analysis, 2025" explores a diverse pipeline targeting the world's leading cause of morbidity and mortality. Despite the…
Anthrax Clinical Trials Analysis 2025: Next-Generation Vaccines, Monoclonal Anti …
DelveInsight's "Anthrax - Clinical Trials Analysis, 2025" reviews an evolving pipeline designed to strengthen protection against Bacillus anthracis infection and biothreat exposure. While antibiotics remain…
Candidiasis Clinical Trials Analysis 2025: Oral Agents, Next-Generation Echinoca …
DelveInsight's "Candidiasis - Clinical Trials Analysis, 2025" examines an active clinical landscape addressing both mucosal (vulvovaginal) and invasive candidiasis. Unmet needs for safe, oral, and…
Necrotizing Enterocolitis Clinical Trials Analysis 2025: Probiotics, HMOs, and R …
DelveInsight's "Necrotizing Enterocolitis (NEC) - Clinical Trials Analysis, 2025" highlights an evolving pipeline aimed at reducing NEC incidence and severity in preterm infants. With NEC…
Brain Hemorrhage Clinical Trials Analysis 2025: Hemostasis, Neuroprotection, and …
DelveInsight's "Brain Hemorrhage - Clinical Trials Analysis, 2025" surveys an active acute-care landscape focused on reducing hematoma expansion, limiting secondary injury, and improving functional recovery…
Cachexia Clinical Trials Analysis 2025: Metabolic Modulators, Anabolic Therapies …
DelveInsight's "Cachexia - Clinical Trials Analysis, 2025" examines a diverse development landscape targeting the complex metabolic, inflammatory, and neurohormonal drivers of cancer- and disease-related wasting.…
Cystitis Clinical Trials Analysis 2025: Novel Antimicrobials, Non-antibiotic Pre …
DelveInsight's "Cystitis - Clinical Trials Analysis, 2025" reviews an active pipeline addressing both uncomplicated and complicated urinary tract infections (UTIs)/cystitis, with emphasis on recurrent cystitis…
Nasopharyngeal Cancer Clinical Trials Analysis 2025: Immunotherapies, Targeted A …
DelveInsight's "Nasopharyngeal Cancer (NPC) - Clinical Trials Analysis, 2025" explores an evolving pipeline focused on improving outcomes for patients with advanced or recurrent disease. Despite…
Hereditary Angioedema Clinical Trials Analysis 2025: Novel Therapeutics, Prophyl …
DelveInsight's "Hereditary Angioedema (HAE) - Clinical Trials Analysis, 2025" reviews a rapidly evolving clinical pipeline designed to prevent and manage acute HAE attacks. Despite available…
Cutaneous Lupus Erythematosus Clinical Trials Analysis 2025: Targeted Immunomodu …
DelveInsight's "Cutaneous Lupus Erythematosus (CLE) - Clinical Trials Analysis, 2025" highlights a dynamic pipeline addressing persistent gaps in treatment for patients with lupus-specific skin manifestations.…
Febrile Neutropenia Clinical Trials Analysis 2025: Antimicrobial Stewardship, No …
DelveInsight's "Febrile Neutropenia - Clinical Trials Analysis, 2025" reviews an evolving pipeline focused on reducing infection-related complications in cancer patients undergoing chemotherapy. Despite advances in…
Vasculitis Clinical Trials Analysis 2025: Targeted Immunotherapies, Complement I …
DelveInsight's "Vasculitis - Clinical Trials Analysis, 2025" highlights a dynamic pipeline aimed at improving remission durability and minimizing steroid dependence in this group of rare,…
Advanced Gastric Carcinoma Clinical Trials Analysis 2025: Targeted Agents, Immun …
DelveInsight's "Advanced Gastric Carcinoma (AGC) - Clinical Trials Analysis, 2025" reviews a rapidly evolving clinical pipeline focused on enhancing overall survival, response durability, and tolerability…
Advanced Urothelial Carcinoma Clinical Trials Analysis 2025: Targeted Therapies, …
DelveInsight's "Advanced Urothelial Carcinoma (aUC) - Clinical Trials Analysis, 2025" examines a dynamic pipeline focused on improving survival, response rates, and tolerability for patients with…
Post-Polycythemia Vera Myelofibrosis Clinical Trials Analysis 2025: Novel JAK In …
DelveInsight's "Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Clinical Trials Analysis, 2025" highlights an evolving pipeline designed to tackle the limitations of current therapies and improve long-term…
Immunologic Deficiency Syndrome Clinical Trials Analysis 2025: Gene Therapies, N …
DelveInsight's "Immunologic Deficiency Syndrome - Clinical Trials Analysis, 2025" reviews the rapidly evolving clinical landscape for primary and selected secondary immunodeficiency disorders, a heterogeneous group…
Vestibular Schwannoma Clinical Trials Analysis 2025: Hearing-Preservation Strate …
DelveInsight's "Vestibular Schwannoma - Clinical Trials Analysis, 2025" examines the evolving clinical-trial landscape for vestibular schwannoma (VS). This typically benign cranial nerve tumor can cause…
